Research Letter

Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists

Vinayak Muralidhar, MD, MSc, a,b Nicholas J. Giacalone, MD, a,b Nastaran Milani, MPH, b Jonathan D. Schoenfeld, MD, DPhil, MPH, b Roy B. Tishler, MD, PhD, b Bhupendra Rawal, MS, c and Danielle N. Margalit, MD, MPH b, *

aHarvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts; b Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Boston, Massachusetts; and c Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

Received 2 August 2020; revised 12 October 2020; accepted 17 October 2020

Abstract
Purpose: Many improvements in head and neck cancer (HNC) outcomes are related to optimization of radiation therapy (RT) dose, fractionation, normal-tissue sparing, and technology. However, prior work has shown that the literature of randomized controlled trials is dominated by industry-sponsored trials that have lower rates of incorporating RT. We characterized HNC clinical trials, hypothesizing that RT-specific research questions may be relatively underrepresented among HNC randomized controlled trials.

Methods and Materials: A web query of all open interventional trials on www.ClinicalTrials.gov was performed using search terms “head and neck cancer” and specific HNC subsites. Trial details were captured including the modality used, principal investigator (PI) specialty, funding, and whether the study tested a RT-modality specific hypothesis. Chi-square testing and logistic regression were used to compare groups.

Results: There were 841 open HNC trials, including definitive (47.6%) and recurrent/metastatic (41.9%) populations. Most trials (71.7%) were phase I or nonrandomized phase II studies, rather than phase III or randomized phase II (28.3%). Among single-arm studies, most (79.6%) incorporated systemic therapy (ST), and fewer (25.2%) incorporated RT. Even fewer phase III and randomized phase II trials tested an RT-specific hypothesis (11.1%), compared with ST-related hypotheses (77.1%; \( P < .001 \)); trials were more likely to test an RT-hypothesis if the study PI was a radiation oncologist (20.9% vs 6.0%; \( P < .001 \)). Among RT trials, most early-phase studies tested novel modalities (eg, stereotactic body radiation therapy, proton therapy), whereas most later-phase studies tested dose and fractionation. RT-focused trials had low rates of federal (10.4%) or industry (2.6%) funding.

Conclusions: RT-specific research hypotheses are a minority of phase II-III HNC trials, which mostly focus on incorporating ST in the definitive or recurrent/metastatic setting and have higher rates of industry funding. Radiation oncologist PI leadership and increased nonindustry funding access may ensure that RT-specific hypotheses are incorporated into trial design.

© 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Disclosures: Dr Schoenfeld reports grants and personal fees from Bristol-Meyers-Squibb, grants from Merck, grants from Regeneron, personal fees from Debiopharm Group, personal fees from AstraZeneca, personal fees from Nanobiotix, personal fees from Tilos Therapeutics outside the submitted work. Dr Tishler reports participation on advisory board (Regeneron), Data Safety Monitoring Boards for (PRA/Enzychem), and PSI/Orangeics. Dr Margalit reports personal fees from Galera Therapeutics in 2018 outside the submitted work.

* Corresponding author: Danielle Margalit, MD, MPH; E-mail: Danielle_Margalit@dfci.harvard.edu

https://doi.org/10.1016/j.adro.2020.10.021

2452-1094/© 2020 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).


Introduction

We aimed to characterize clinical trials in head and neck cancer (HNC) and the frequency of radiation therapy (RT)—related research questions, especially for phase III and randomized phase II trials, which have the greatest potential to change long-term practice patterns.

Methods and Materials

A search was performed on June 26, 2017, of www.ClinicalTrials.gov for open interventional clinical trials using search terms “head and neck cancer” and specific subtypes: “salivary gland cancer,” “paranasal sinus cancer,” “nasal cavity cancer,” “nasopharyngeal cancer,” “oral cavity cancer,” “larynx cancer,” “hypopharynx cancer,” “oropharynx cancer,” “thyroid cancer.” Studies were excluded if they did not include HNC or exclusively enrolled pediatric patients. Other details regarding data collection and classification were previously published. For each study, the authors characterized the treatment modalities included, trial characteristics, and whether the study tested an RT-specific hypothesis. Most quality-of-life or survivorship studies (56.9%) were tested in the RT hypothesis (including comparing RT dose, fractionation, modality, use of RT, imaging, or other), an systemic therapy (ST)—specific hypothesis, or both. Chi-square testing and logistic regression were used to identify associations among trial characteristics, including study question, study principal investigator (PI) specialty, and study funding. A P value of \( \leq .05 \) was considered statistically significant.

Results

Trial characteristics

Table 1 demonstrates the clinical trial characteristics for the study cohort (n = 841). Most trials were phase I/nonrandomized phase II trials (71.7%), rather than phase III/randomized phase II (28.3%). Among single-arm trials, most (n = 363, 79.6%) incorporated ST, 241 (52.9%) were ST-only, 115 (25.2%) incorporated RT, 30 (6.6%) were RT-alone trials, and 34 (7.5%) included surgery.

Among phase III and randomized phase II trials (n = 253), 11.1% tested a RT-specific hypothesis, compared with 77.1% testing an ST-specific hypothesis (\( P < .001 \)). Trials were more likely to test an RT-specific hypothesis if one of the study PIs was a radiation oncologist (RO) (20.9% vs 6.0%; \( P < .001 \)). When the analysis was restricted to phase III and randomized phase II trials incorporating RT as a treatment modality, there was still a higher, but not statistically different, percentage of trials testing an RT-specific hypothesis if the PI was an RO (22.5% vs 13.2%; \( P = .129 \)).

Characteristics of radiation trials

Among single-arm RT-alone trials (n = 33), most (63.6%) tested treatment modalities (eg, stereotactic treatment, proton therapy) or imaging modalities (eg, positron emission tomography), rather than radiation dose/fractionation (21.2%). Among phase III and randomized phase II RT trials (n = 28), 50% tested dose/fractionation (eg, dose de-escalation, hyperfractionation), 21.4% tested the need for any RT, and 17.9% evaluated RT treatment modalities.

Funding sources

Among all HNC trials, 14.4% had National Institutes of Health (NIH) or other federal funding, 31.8% had industry funding, and 79.6% had other sources of funding; 25.1% of trials had more than 1 source of funding. Funding rates among these sources were similar for phase I/nonrandomized phase II trials and for phase III/randomized phase II trials (\( P > .05 \)).

Funding sources differed significantly by whether trials tested an RT-specific hypothesis. Rates of NIH funding were similar for RT and non-RT trials (10.4% vs 14.8%; \( P = .294 \)), but trials testing an RT hypothesis were much less likely to have industry funding compared with other trials (2.6% vs 34.7%; \( P < .001 \)) and were more likely to have “other” funding (100% vs 77.5%; \( P < .001 \)).

Survivorship and quality of life

Of the 385 multiarm trials in the cohort, 72 (18.7%) tested a survivorship or quality-of-life question, such as interventions to reduce side effects from treatment. These trials were less likely to have industry funding compared with other multiarm trials (6.9% vs 30.4%; \( P < .001 \)) and more likely to have federal funding (19.4% vs 10.5%; \( P = .038 \)) or other funding (97.2% vs 80.5%; \( P = .001 \)). Most quality-of-life or survivorship studies (56.9%) were led by PIs who were not ROs, medical oncologists, or surgeons (eg, speech-language pathologists, dentists, nurses).

Discussion

This analysis of HNC clinical trials on www.ClinicalTrials.gov shows that approximately half of all studies (47.6%) were focused on the definitive/curative patient population and the rest were mostly focused on the recurrent/metastatic population (41.9%). Only 11.1% of phase III/randomized phase II trials, which are the most likely studies to influence long-term practice patterns, tested a radiation-specific hypothesis such as dose, fractionation, or other radiation-specific question. Trials were
more likely to test an RT hypothesis if 1 of the study PIs was an RO (20.9% vs 6.0%; \( P < .001 \)). Most (77.1%) phase III/randomized phase II clinical trials tested ST-related hypotheses, often in conjunction with standard RT or surgical treatment.

These findings suggest that RO leadership is important to design large phase III/randomized phase II trials that evaluate the full potential of RT innovation—whether using novel treatment modalities, determining the optimal way to combine RT with ST, or pushing the envelope in adaptive replanning, dose, fractionation, and modification of standard treatment volumes. This is particularly important in HNC given the potential value of dose intensification in high-risk disease such as larynx/hypopharynx HNC or for deintensification of RT in p16-positive oropharyngeal cancer.2

Funding source significantly differed by the type of study question, with industry rarely funding radiation trials or survivorship-related questions, which may not be surprising because improvements in radiation that do not involve new technological innovation do not always offer a patentable innovation. Prior work also demonstrated that both radiation and surgery, standard-of-care modalities for HNC treatment, have low rates of industry and NIH funding.3 Furthermore, head-to-head randomized trials were previously shown to be dominated by industry-sponsored comparisons, with results that tend to favor industry particularly when noninferiority designs were used.4 Further restrictions on federal funding availability may shrink funding sources for trials of radiation-specific hypotheses. The relative availability of industry-funding may end up driving trial design and the future of HNC research rather than preclinical data-driven hypotheses that do not necessarily incorporate novel ST.

Limitations of our work include incomplete capture of all ongoing trials since www.ClinicalTrials.gov represents just 1 registry of trials (albeit capturing approximately 80% of all ongoing trials worldwide) and the time-dependent nature of this cross-sectional study. There is also limited information on variables such as “other” funding sources, due to limitations in the amount of specific detail provided by the database. Yet, each trial was individually queried with additional web-searching performed to determine as much detail as possible.

Most HNC trials, both in the recurrent/metastatic and definitive setting, focus on ST. This represents an opportunity for ROs to increase efforts to study radiation-specific questions and to explore how RT can synergize with ST.5-7 Maximizing the potential for investigating RT-specific research questions will depend on increasing federal funding and other nonindustry funding sources, especially for research that seeks to

### Table 1  Clinical trial characteristics for the study cohort (n = 841)

| Trial enrollment location                  | n  | %    |
|-------------------------------------------|----|------|
| US only                                   | 404| 48.0%|
| International only                        | 365| 43.4%|
| US and international                      | 66 | 7.8% |
| Unknown                                   | 6  | 0.7% |
| Funding source                            |    |      |
| Any NIH/US federal government             | 121| 14.4%|
| Any industry                             | 264| 31.4%|
| Other                                     | 669| 79.5%|
| Phase                                     |    |      |
| I                                         | 181| 21.5%|
| II                                        | 382| 45.4%|
| III                                       | 115| 13.7%|
| IV                                        | 15 | 1.8% |
| Unknown                                   | 148| 17.6%|
| Patient population                        |    |      |
| Definitive                                | 400| 47.6%|
| Recurrent/malignant                       | 352| 41.9%|
| Definitive or recurrent/malignant         | 47 | 5.6% |
| Other                                     | 42 | 5.0% |
| PI specialty                              |    |      |
| Radiation oncology                        | 197| 23.4%|
| Medical oncology                          | 287| 34.1%|
| Surgery                                   | 134| 15.9%|
| Other                                     | 239| 28.4%|
| Modality used in clinical trial           |    |      |
| Any drug                                  | 639| 76.0%|
| Any radiation                             | 414| 49.2%|
| Any surgery                              | 100| 11.9%|
| Single arm trials (n = 456)               |    |      |
| Incorporating RT                          | 115| 25.2%|
| Incorporating drug                        | 363| 79.6%|
| Incorporating surgery                     | 34 | 7.5% |
| Other                                     | 46 | 10.1%|
| Multiarm trials (n = 385)                 |    |      |
| Drug only studies                         | 78 | 20.3%|
| RT and drug                               | 113| 29.4%|
| RT alone                                  | 16 | 4.2% |
| Surgery alone                             | 14 | 3.6% |
| Surgery, drug, and RT                     | 15 | 3.9% |
| Quality of life/survivorship study        | 72 | 18.7%|
| Mucositis or dermatitis prevention        | 36 | 9.4% |
| Other                                     | 41 | 10.6%|
| Disease site (definitive trials only)     |    |      |
| Larynx/hypopharynx                        | 12 | 3.1% |
| Nasopharynx                               | 60 | 15.3%|
| Oral cavity                               | 23 | 5.9% |
| Oropharynx                                | 33 | 8.4% |
| Multiple (>1 site included)               | 235| 59.9%|
| Thyroid                                   | 21 | 5.4% |
| Other                                     | 8  | 2.0% |

Abbreviations: NIH = National Institutes of Health; PI = principle investigator; RT = radiation therapy; US = United States.
deintensify therapy by omitting ST altogether. Examples of ways to increase federal and foundation funding for RT-specific research include increased RO representation on federal grant review committees, increased financial support of RT-focused funding organizations (eg, Radiation Oncology Institute), and advocacy at the federal level to specifically increase funding for RT-related research to fill the gap caused by preferential funding of ST-related research by industry sources. Lastly, and perhaps most importantly, our field can nurture future clinician-scientists and clinician-trialists at the residency level. Opportunities for basic science research, such as the Holman Pathway, give residents the tools to identify preclinical and translational study questions. Coursework in clinical trial design and mentorship in industry collaboration are all early-career ways to provide ROs with the skills needed to cultivate the future of our field. This relies on subsequent departmental support and investment in such clinician-scientists and clinician-trialists as junior faculty and beyond.

References

1. Giacalone NJ, Milani N, Rawal B, et al. Funding support and principal investigator leadership of oncology clinical trials using radiation therapy. Int J Radiat Oncol Biol Phys. 2018;102:34-43.
2. Adelstein DJ, Ismaila N, Ku JA, et al. Role of treatment deintensification in the management of p16+ oropharyngeal cancer: ASCO provisional clinical opinion. J Clin Oncol. 2019;37:1578-1589.
3. Devaiah A, Murchison C. Characteristics of NIH- and industry-sponsored head and neck cancer clinical trials. Laryngoscope. 2016;126:E300-E303.
4. Flacco ME, Manzoli L, Boccia S, et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. J Clin Epidemiol. 2015;68:811-820.
5. Pignon JP, le Maître A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
6. Johnson CB, Jagsi R. The promise of the abscopal effect and the future of trials combining immunotherapy and radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:1254-1256.
7. Morris ZS, Harari PM. Interaction of radiation therapy with molecular targeted agents. J Clin Oncol. 2014;32:2886-2893.